SI
SI
discoversearch

Biotech / Medical
Provectus Pharmaceuticals Inc.
An SI Board Since April 2006
Posts SubjectMarks Bans Symbol
13087 111 0 PVCT
Emcee:  Jack Russell Type:  Moderated



This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.

Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.

-----------------------------------------------------------------------------------------------------------------------------------------------


PV-10 link to video and visual references:

http://www.pvct.com/multimedianews.html





PV-10 Trial Participants Telling Their Own Stories in the News

http://www.pvct.com/pv10-videos.html





May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.
Video can be viewed here.

http://www.pvct.com/hersey_pv10_video.html?pg=2

This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.
Video can be viewed here.
http://www.pvct.com/hersey_pv10_video.html?pg=5





2008, Charles Dawson, PV10 patient, Australia; Professor John Thompson, Sydney Melanoma Unit

Video can be viewed here

https://www.youtube.com/watch?v=HSjoev_q9Nw





December 16, 2010
Madja Rauh recently traveled to Bethlehem with her daughter Ursa Rauh from Ljubljana, the capital of Slovenia in Europe, to receive a promising, experimental treatment for metastatic melanoma with internationally recognized melanoma investigator Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology, St. Luke's Hospital & Health Network,Bethlehem, PA

Video can be viewed here.

http://www.slhn.org/News/2010/Slovenian-Woman-Receives-Treatment

http://www.pvct.com/inthenews.html?article=20110725&mode=0
Madja Rauh, PV10 patient, has a Facebook page as of 1/ 2015


http://www.pvct.com/inthenews.html?article=20070321&mode=0


http://www.pvct.com/inthenews.html?article=20110725&mode=0
Madja Rauh, PV-10 patient, has a Facebook page as of January 2015

--------------------------------------------------------------


Contact Info

Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
E-mail: Laura.Skorny@Broadridge.com
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302


Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075
marlon@plrinvest.com


Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
bill@plrinvest.com


Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031



-----------------------------------------------------------
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
13087I doubt it... But you never know. What makes you think this?Jack Russell-Tuesday
13086or de-listing in the US?NTTG-Tuesday
13085They (Provectus) are winding down the cup program in Australia and now setting uJack Russell-June 16
13084New CTD... An Australian office? (June 16, 2016) Provectus incorporated its AusJack Russell-June 16
13083If this is PV-10 and my guess is that it is its pretty sad they have to go to a Jack Russell-June 16
13082Protocols look the same as PV-10... Side effects look the same as PV-10... InjecJack Russell1June 16
13081They state the side effects are very minimal...Jack Russell-June 15
13080More on that Footballer in Australia. This article says Grant McArthur is treatiJack Russell-June 15
13079Interesting piece from Australia on one of their sports stars and Melanoma. He iJack Russell-June 15
13078CTD Proxy vote... provectuspharmaceuticalsinc.blogspot.comJack Russell-June 14
13077Alan Ross on management compensation... trustintelligence.comJack Russell-June 12
13076I would be happy to move back here. KhrisKhris Smith-June 10
13075Just bought 5000 more...Jack Russell-June 10
13074Hey! 1,000,000+ shares. Up 20% to over .50. Why no action on this thread? Bob Miller-April 28
13073Hey Willie J whats your beef...Jack Russell-February 27
13072The street.com wallstreet.orgJack Russell-February 4
13071 Provectus Biopharma (PVCT) Confirms Dosing in PV-10 Phase 3 streetinsider.comJack Russell-January 12
13070I am glad it worked out for him... And the ridiculous part of your statement isJack Russell-January 7
13069Jack.... no doubt you disagree, but the facts are the facts...and frail old JimmNTTG-January 5
13068I would disagree... Good for Mr Carter I am happy for him... The Side affects ofJack Russell-12/10/2015
13067Lets see...they successfully completed a PIII, got FDA approval, and are now beiNTTG-12/7/2015
13066LOL TVEC does little beyond the horrible side affects....Jack Russell-12/3/2015
13065I have no issue with T Vec data or the MOA. It will be interesting to watch theiNTTG-12/3/2015
13064Yawn, more nondescript mousey dataNTTG-11/9/2015
13063Provectus Biopharmaceuticals Reports Immune Mechanism of Action Data for PV-10 Jack Russell-11/6/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.